Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tocilizumab in Hemophagocytic Lymphohistiocytosis and Cytokine Release Syndrome
NCT02007239Phase 2Withdrawn
- Sponsor
- Children's Hospital of Philadelphia
- Start
- Dec 2013
- Primary completion
- May 2021
- Modality
- Antibody Conjugates, Recombinant Proteins and Enzymes, Engineered Antibody Formats
- Countries
- 1
01
Overview
A Phase 2 trial of tocilizumab in hemophagocytic lymphohistiocytosis (HLH), cytokine release syndrome (CRS), sponsored by Children's Hospital of Philadelphia. Planned start Dec 2013; status: withdrawn.
02
Drugs
tocilizumab
03
Conditions
hemophagocytic lymphohistiocytosis (HLH)cytokine release syndrome (CRS)
Beyond the preview
Go deeper on NCT02007239.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02007239.